Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Agreements represent final steps needed in order to commence...

Autonomix Medical, Inc. Successfully Completes Preclinical Safety Study to Support Program Advancement into First-in-Human Clinical Study to Treat Pancreatic Cancer Pain Through Transvascular Ablation Patented two-fold technology in development to locate, ablate and confirm successful ablation of specific nerves for pain management and other uses All safety inputs met with no reported...